SXTP
60 DEGREES PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.83
−3.29%Year over year
Reported trailing growth
- Revenue
- +68.0%
- EBITDA
- -3.4%
- EBIT
- -11.7%
- EPS
- +81.5%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +53.9%
- EBITDA
- -9.2%
- EPS
- +44.5%
Three-year CAGR
- Revenue
- +65.2%
- EBITDA
- +7.7%
- EBIT
- +20.1%
- Net income
- +7.3%
- EPS
- +84.2%
- Free cash flow
- -21.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026